Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm,
multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and
pharmacokinetics (PK) of NBI-1117568 compared with placebo in adult subjects with a primary
diagnosis of schizophrenia, who are experiencing an acute exacerbation or relapse of
symptoms.